Company: WHWK
Filing Date: 2025-01-21
Form Type: PREM14A
Source: 0001193125-25-009599
Chunk: 261

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-21
Form: PREM14A
Chunk 261
---
 million of license expense in the fourth quarter of 2021 and had a corresponding $0.2 million sublicense payable to BMS as of December 31, 2021, which was paid in 2022. On June 27, 2022, we received written notice from EOC that EOC elected to terminate the EOC License Agreement, effective immediately. On June 27, 2022, EOC filed a Request for Arbitration with the International Chamber of Commerce’s International Court of Arbitration against us. On September 26, 2024, the arbitration panel issued a Final Award which, among other things, found and concluded that we did not breach the EOC License Agreement and accordingly we are not liable for any damages to EOC. See Notes 7 and 12 to our unaudited condensed consolidated financial statements and the related notes thereto included elsewhere in this proxy statement for more information about the EOC License Agreement, its termination and the arbitration proceedings. Former Mirati Collaboration In October 2022, we entered into a collaboration and supply agreement with Mirati to evaluate the combination of Mirati’s adagrasib and FYARRO in KRAS G12Cmutant NSCLC and other solid tumors. In May 2024, we announced the mutually agreed upon termination of the collaboration and G12C supply agreement with Mirati. Enrollment in the Phase 1/2 study has been closed and the study is winding down. Under the terms of the agreement, Mirati was responsible for sponsoring and operating the Phase 1/2 study and we supplied study drug and jointly shared the cost of the study, which will continue during the winding down process. Key Trends and Factors Affecting Comparability Between Periods

| • |     | Commercial sale of FYARRO was launched on February 22, 2022, for the treatment of patients with advanced                                                                                                                               
 malignant PEComa. We recorded net product sales of $7.2 million and $18.7 million during the three and nine months ended September 30, 2024, respectively. We recorded net product sales of $24.4 million and $15.2 million during the 
 years ended December 31, 2023 and 2022, respectively.                                                                                                                                                                                  |

- 181 -

| • |     | We expect to decrease our investment in research and development as a result of our halt and subsequent wind-down                                                   
 of the PRECISION1 study following interim data results and the pause of enrollment